| 1 |
NCT02026089 |
Not yet recruiting |
Persistence of Varicella Immunity in Hospital Employees Receiving Varicella Vaccine |
- Persistence of Varicella Immunity
|
- Biological: Varicella vaccine
|
Interventional |
Phase 4 |
- University of Colorado, Denver
- Centers for Disease Control and Prevention
|
Other / U.S. Fed |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
|
- Determine the proportion of employees who 5 years previously received varicella vaccine at the time of employment who no longer have varicella-specific antibody.
- Determine the avidity (strength with which the vaccine induced antibody binds to the varicella antigen) of varicella-specific antibody in vaccinated employees.
|
100 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02026089 |
13-1380 |
|
October 2018 |
December 2018 |
December 2018 |
January 1, 2014 |
January 23, 2018 |
|
- Children's Hospital Colorado
Aurora, Colorado, United States
|
| 2 |
NCT02329457 |
Recruiting |
VZV Vaccine for Hematopoietic Stem Cell Transplantation |
- Varicella Zoster Infection
|
- Biological: Zostavax
- Biological: Normal Saline
|
Interventional |
Not Applicable |
- The University of Hong Kong
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Immunological response in donors
- Herpes zoster reactivation
- Adverse reaction
|
120 |
All |
18 Years to 60 Years (Adult) |
NCT02329457 |
HKU 11-174 |
VZIDST |
December 2014 |
March 2018 |
August 2018 |
December 31, 2014 |
July 28, 2017 |
|
- Ivan Hung
Hong Kong, Hong Kong
|
| 3 |
NCT00492739 |
Recruiting |
Immunity Against Varicella in Pediatric Orthotopic Liver Transplantation Recipients |
- Liver Disease
- Immunosuppression
- Varicella
|
- Biological: Vaccination with VZV vaccine
|
Interventional |
Phase 2
Phase 3 |
- University Hospital, Geneva
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety of VZV vaccine in OLTx recipients
- Efficacy of VZV vaccine in immunosuppressed OLTx recipients
|
80 |
All |
up to 18 Years (Child, Adult) |
NCT00492739 |
VZVinOLTx |
VZVinOLTx |
June 2007 |
April 2017 |
December 2017 |
June 27, 2007 |
December 30, 2016 |
|
- Children's Hospital of Geneva (HUG)
Geneva, GE, Switzerland
|
| 4 |
NCT03330171 |
Recruiting |
Safety and Immunogenicity of Measles Vaccine, Varicella Vaccine and Hepatitis-A Vaccine |
- Measles
- Varicella
- Hepatitis A
|
- Biological: Measles vaccine
- Biological: Hepatitis-A vaccine
- Biological: Varicella vaccine
|
Interventional |
Phase 4 |
- University of Witwatersrand, South Africa
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Number of participants with seroprotective antibody titres (IgG ≥330 mIU/ml quantified by ELISA) one month post booster measles vaccination
- Number of participants with seroprotective antibody titres (IgG ≥300 mIU/ml quantified by ELISA) one month post varicella vaccination
- Number of participants with seroprotective antibody titres (IgG ≥20 mIU/ml quantified by ELISA) one month post hepatitis-A vaccination
- (and 4 more...)
|
270 |
All |
18 Weeks to 19 Months (Child) |
NCT03330171 |
MV/VV/Hep-AV |
MV/VV/Hep-AV |
April 10, 2017 |
February 2019 |
June 2019 |
November 6, 2017 |
November 6, 2017 |
|
- Chris Hani Baragwanath Academic Hospital; Nrf/Dst Vpd Rmpru
Soweto, Gauteng, South Africa
|
| 5 |
NCT03509701 |
Not yet recruiting
New |
Reversible Cerebral Vasoconstriction Syndrome and Varicella Zoster Virus |
- Reversible Cerebral Vasoconstriction Syndrome
- Varicella-zoster Virus Infection
|
- Diagnostic Test: Varicella zoster virus specific T-cell mediated immune response
|
Observational |
|
- Asan Medical Center
- Hanyang University
- Nowon Eulji Medical Center, Eulji University
- Kangbuk Samsung Hospital
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
- Infection or reactivation of varicella zoster virus (VZV)
|
40 |
All |
20 Years to 79 Years (Adult, Senior) |
NCT03509701 |
2018-0385 |
RCVS&VZV |
May 1, 2018 |
April 30, 2020 |
April 30, 2020 |
April 26, 2018 |
April 26, 2018 |
|
|
| 6 |
NCT03178747 |
Recruiting |
Tzanck Smear With Methylene Blue Stain for Herpes |
- Herpes Simplex
- Herpes Zoster
- Varicella Zoster
|
- Diagnostic Test: Methylene blue
- Diagnostic Test: Giemsa stain
|
Interventional |
Phase 3 |
- Chulalongkorn University
- Dermatological Society of Thailand
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Diagnostic
|
- Sensitivity
- Factors that contribute the results from Methylene blue staining
- Specificity
|
150 |
All |
18 Years and older (Adult, Senior) |
NCT03178747 |
674/59 |
|
March 7, 2017 |
December 7, 2017 |
March 6, 2018 |
June 7, 2017 |
August 4, 2017 |
|
- Division of Dermatology, Faculty of Medicine, Chulalongkorn University
Bangkok, Thailand
|
| 7 |
NCT03239873 |
Recruiting |
Evaluation of Immunogenicity and Safety of VARIVAX™ Passage Extension 34 (PE34) Process in Children (V210-A03) |
|
- Biological: VARIVAX™ PE34 Process
- Biological: VARIVAX™ 2016 Commercial Process
- Biological: M-M-R II™
|
Interventional |
Phase 3 |
- Merck Sharp & Dohme Corp.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- Varicella Zoster Virus (VZV) Antibody Response Rate
- Varicella Zoster Virus (VZV) Geometric Mean Titer
- Elevated Temperature
- (and 14 more...)
|
600 |
All |
12 Months to 23 Months (Child) |
NCT03239873 |
V210-A03 |
|
October 17, 2017 |
October 9, 2018 |
April 19, 2019 |
August 4, 2017 |
March 8, 2018 |
|
- Alabama Clinical Therapeutics ( Site 0018)
Birmingham, Alabama, United States - Children's Clinic of Jonesboro, PA ( Site 0030)
Jonesboro, Arkansas, United States - Southland Clinical Research Center ( Site 0017)
Anaheim, California, United States - (and 34 more...)
|
| 8 |
NCT02775422 |
Recruiting |
Comparison of Serological Test s for the Virus Chicken Pox Virus (VZV) and Correlation With the Patient's Memory of the Infection or Vaccination |
|
- Biological: Serological Test s for the Virus Chicken Pox Virus
|
Interventional |
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Rate sensitivity and specificity in negative and dubious zone for the assessment of the serology of anti VZV immunity
- frequency of immunity detecting depending on whether the patient remember having varicella, have been in contact with next of kin with varicella or been vaccinated against varicella or not
- Percentage of women accepting the vaccination in case of negative history
|
400 |
Female |
18 Years and older (Adult, Senior) |
NCT02775422 |
2014/08
2014-A00707-40 |
VARI-IMM |
March 2015 |
February 2018 |
February 2018 |
May 17, 2016 |
February 1, 2017 |
|
- Hopital Foch
Suresnes, France
|
| 9 |
NCT03493776 |
Recruiting
New |
Safety and Immunogenicity of Non-live, Recombinant Subunit Herpes Zoster Vaccine Before and After Lung Transplantation |
|
- Biological: VZV subunit vaccine
|
Interventional |
Phase 4 |
- Deepali Kumar
- University Health Network, Toronto
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Prevention
|
- Cellular immunity to varicella zoster induced by varicella zoster subunit vaccine.
- Humoral immunogenicity to varicella zoster induced by varicella zoster subunit vaccine in lung transplant recipients.
- Humoral immunogenicity to varicella zoster induced by varicella zoster subunit vaccine in post-transplant group vs. pre-transplant group
|
75 |
All |
50 Years and older (Adult, Senior) |
NCT03493776 |
UHN-Shingrix-001 |
|
April 15, 2018 |
September 5, 2019 |
March 5, 2020 |
April 10, 2018 |
April 10, 2018 |
|
- University Health Network, Toronto General Hospital, Multi-Organ Transplant
Toronto, Ontario, Canada
|
| 10 |
NCT02689700 |
Recruiting |
Diaplacental Transfer of Anti-HCMV- and Anti-VZV-immunoglobulin G (IgG) -Antibodies at Premature and Mature Newborns |
- Materno-fetal Transfer of Anti-HCMV-IgG
- Materno-fetal Transfer of Anti-VZV-IgG
|
|
Observational |
|
- Johann Wolfgang Goethe University Hospital
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- To measure the concentration of specific HCMV-/VZV-IgG-antibodies in fetal bloodstream depending on gestational age at birth.
- Gauging the concentration of neutralizing IgG-antibodies against HCMV and VZV in fetal bloodstream depending on gestational age at birth.
|
450 |
All |
up to 10 Minutes (Child) |
NCT02689700 |
040713 FRA Mat Fet CMV Antib |
MoChi-HCMV |
July 2013 |
December 2017 |
July 2018 |
February 24, 2016 |
March 7, 2017 |
|
- Clinic of the Johann Wolfgang-Goethe Univeristy
Frankfurt/Main, Hesse, Germany
|
| 11 |
NCT03314103 |
Recruiting |
Efficacy Trial of a Vaccine to Prevent Herpes Zoster in Adults Over 40 Years of Age |
|
- Biological: One shot of the varicella-zoster virus vaccine
- Biological: one shot of placebo
|
Interventional |
Phase 3 |
- Jiangsu Province Centers for Disease Control and Prevention
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- The incidence of herpes zoster 30 days after vaccination.
- The incidence of herpes zoster after vaccination.
- The incidence of laboratory-confirmed herpes zoster 30 days after vaccination.
- (and 10 more...)
|
30000 |
All |
40 Years and older (Adult, Senior) |
NCT03314103 |
CS-HZ-2017 |
|
October 6, 2017 |
October 30, 2019 |
December 30, 2019 |
October 19, 2017 |
October 19, 2017 |
|
- Hunan Provincial Center for Disease Control and Prevention
Loudi, Hunan, China - Jiangsu Province Centers for Disease Control and Prevention
Nanjing, Jiangsu, China - Zhejiang Provincial Center for Disease Control and Prevention
Hanzhou, Zhejiang, China
|
| 12 |
NCT02687763 |
Recruiting |
Safety and Efficacy of ProQuad® in Children 6-24 Month Being Evaluated for Solid Organ Transplant |
- RENAL INSUFFICIENCY, CHRONIC
- LIVER FAILURE, ACUTE
- HEART DISEASE
|
|
Interventional |
Phase 1
Phase 2 |
- Medical University of South Carolina
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
|
- Varicella IgG Antibody Titer ≥ 1.1 IU/ml
- Measles IgG Antibody Titer ≥ 30AU/ml
- Mumps IgG Antibody Titer ≥ 11AU/ml
- (and 5 more...)
|
45 |
All |
6 Months to 24 Months (Child) |
NCT02687763 |
Pro25854 |
ProQuad® |
December 2015 |
December 2017 |
January 2018 |
February 22, 2016 |
March 23, 2017 |
|
- Medical University of South Carolina, Pediatric Nephrology
Charleston, South Carolina, United States
|
| 13 |
NCT03134196 |
Recruiting |
Zoster Eye Disease Study |
- Herpes Zoster Ophthalmicus
|
- Drug: Masked Placebo
- Drug: Masked Oral Valacyclovir
|
Interventional |
Phase 4 |
- New York University School of Medicine
- National Eye Institute (NEI)
- National Institutes of Health (NIH)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Time to first occurrence of Dendriform epithelial keratitis, Stromal keratitis, Endothelial keratitis or Iritis
|
1050 |
All |
18 Years and older (Adult, Senior) |
NCT03134196 |
16-00463
1U10EY026869 |
ZEDS |
August 23, 2017 |
December 31, 2020 |
December 31, 2020 |
April 28, 2017 |
March 16, 2018 |
|
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Jules Stein Eye Clinic - UCLA
Los Angeles, California, United States - Pacific Eye Surgeons, Inc.
San Luis Obispo, California, United States - (and 40 more...)
|
Create an RSS feed from your search for:
Download the search results for: